Public Support for Late-Stage New Drug Discovery

Objective: To determine the role of publicly-supported research in the development of innovative new medications.Design: We examined patent data and drug discovery and development histories to assess the extent of public support for late-stage medication development.Setting: All new drugs approved c...

Full description

Saved in:
Bibliographic Details
Main Author: Nayak, Rahul K
Format: Dissertation
Language:English
Published: ProQuest Dissertations & Theses 01-01-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Objective: To determine the role of publicly-supported research in the development of innovative new medications.Design: We examined patent data and drug discovery and development histories to assess the extent of public support for late-stage medication development.Setting: All new drugs approved containing one or more new molecular entity approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway.Main outcome measures: Patents or drug development history documenting late-stage research contributions by publicly funding to an academic center or closely related a spin-off company, as well as each drug’s approval pathway and first-in-class designation.Results: Over the 10-year study period, the FDA approved 248 novel drugs containing one or more new molecular entities. We found that 62 (25%) of these drugs were based at least in part on patents or other late-stage intellectual contributions by publicly-supported research. 48 drugs (19%) had origins in publicly-supported research and development and 14 (6%) originated in in companies spun-off from a publicly-supported research program. Drugs with public-sector provenance were more likely to receive an expediated FDA approval or be designated first-in-class, indicating their relative therapeutic importance.Conclusions: A review of the patents associated with new drugs approved over the last decade indicates that publicly-supported research played a major role in the development of a substantial proportion of new medications, either through direct funding of late-stage research or the creation of resultant spin-off companies. This may have implications for policy makers in determining fair prices and revenue flows for these products.
AbstractList Objective: To determine the role of publicly-supported research in the development of innovative new medications.Design: We examined patent data and drug discovery and development histories to assess the extent of public support for late-stage medication development.Setting: All new drugs approved containing one or more new molecular entity approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway.Main outcome measures: Patents or drug development history documenting late-stage research contributions by publicly funding to an academic center or closely related a spin-off company, as well as each drug’s approval pathway and first-in-class designation.Results: Over the 10-year study period, the FDA approved 248 novel drugs containing one or more new molecular entities. We found that 62 (25%) of these drugs were based at least in part on patents or other late-stage intellectual contributions by publicly-supported research. 48 drugs (19%) had origins in publicly-supported research and development and 14 (6%) originated in in companies spun-off from a publicly-supported research program. Drugs with public-sector provenance were more likely to receive an expediated FDA approval or be designated first-in-class, indicating their relative therapeutic importance.Conclusions: A review of the patents associated with new drugs approved over the last decade indicates that publicly-supported research played a major role in the development of a substantial proportion of new medications, either through direct funding of late-stage research or the creation of resultant spin-off companies. This may have implications for policy makers in determining fair prices and revenue flows for these products.
Author Nayak, Rahul K
Author_xml – sequence: 1
  givenname: Rahul
  surname: Nayak
  middlename: K
  fullname: Nayak, Rahul K
BookMark eNrjYmDJy89LZWbgtTS3tDCzNDQytjQ2N-Zg4C0uzkwyMDCwNDY2MDHiZDAIKE3KyUxWCC4tKMgvKlFIyy9S8EksSdUNLklMT1XwSy1XcCkqTVdwySxOzi9LLarkYWBNS8wpTuWF0twMym6uIc4eugVF-YWlqcUl8Vn5pUV5QKl4IxMLQwMDE3MLS2PiVAEAGzs1ag
ContentType Dissertation
Copyright Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Copyright_xml – notice: Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
DBID 04Z
054
0BH
0H~
AMEAF
CBPLH
EU9
G20
M8-
P6D
PQEST
PQQKQ
PQUKI
DatabaseName Dissertations & Theses Europe Full Text: Business
Dissertations & Theses Europe Full Text: Social Sciences
ProQuest Dissertations and Theses Professional
Dissertations & Theses @ Harvard University
ProQuest Dissertations & Theses Global: The Humanities and Social Sciences Collection
ProQuest Dissertations & Theses Global: The Sciences and Engineering Collection
ProQuest Dissertations & Theses A&I
ProQuest Dissertations & Theses Global
ProQuest Dissertations and Theses A&I: The Sciences and Engineering Collection
ProQuest Dissertations and Theses A&I: The Humanities and Social Sciences Collection
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
DatabaseTitle ProQuest Dissertations & Theses Global: The Humanities and Social Sciences Collection
ProQuest One Academic Eastern Edition
ProQuest Dissertations & Theses Global: The Sciences and Engineering Collection
ProQuest Dissertations and Theses Professional
ProQuest Dissertations and Theses A&I: The Sciences and Engineering Collection
ProQuest Dissertations & Theses Global
Dissertations & Theses @ Harvard University
Dissertations & Theses Europe Full Text: Social Sciences
ProQuest One Academic UKI Edition
ProQuest Dissertations and Theses A&I: The Humanities and Social Sciences Collection
Dissertations & Theses Europe Full Text: Business
ProQuest One Academic
ProQuest Dissertations & Theses A&I
DatabaseTitleList ProQuest Dissertations & Theses Global: The Humanities and Social Sciences Collection
Database_xml – sequence: 1
  dbid: G20
  name: ProQuest Dissertations & Theses Global
  url: https://www.proquest.com/pqdtglobal1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Genre Dissertation/Thesis
GroupedDBID 04Z
054
0BH
0H~
8R4
8R5
AMEAF
CBPLH
EU9
G20
M8-
P6D
PQEST
PQQKQ
PQUKI
Q2X
ID FETCH-proquest_journals_24810047893
IEDL.DBID G20
ISBN 9798691239373
IngestDate Thu Oct 10 15:59:24 EDT 2024
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-proquest_journals_24810047893
PQID 2481004789
PQPubID 18750
ParticipantIDs proquest_journals_2481004789
PublicationCentury 2000
PublicationDate 20190101
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 20190101
  day: 01
PublicationDecade 2010
PublicationYear 2019
Publisher ProQuest Dissertations & Theses
Publisher_xml – name: ProQuest Dissertations & Theses
SSID ssib000933042
Score 3.7383935
Snippet Objective: To determine the role of publicly-supported research in the development of innovative new medications.Design: We examined patent data and drug...
SourceID proquest
SourceType Aggregation Database
SubjectTerms Intellectual Property
Medicine
Pharmaceutical sciences
Title Public Support for Late-Stage New Drug Discovery
URI https://www.proquest.com/docview/2481004789
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV09T8MwED3RIiHUSuVTlBZkCVaLOrEce4GhaekALDCwVbbjdEuhJQP_nrs0ERVDF0bLknWyrfO7u-d7ALdOOy0tkdp1UFxmGLAaay33LhbBK-1CddKz1-TlXacTapNz3_yFIVpl4xMrR50tPeXI7yKpqblZos3Dxycn1SiqrtYSGi3YF0IZovQ9bsOfJlrvmsRoZQT1-yKF9D9ut3pLpr3_WnEEnXSriH4Me6E4gYPnukh-CqNNKo6RYCeCa4awlD0hpOQILBeBoVtj6apcMFzFE4Hz-wxuppO38Yw3xszrG7ae_1oSn0O7WBbhAliM8N-6SIZRgkhDBZfnUkTKmhyHXqs-DHetdLl7egCHCBfMJgExhPbXqgxX0Fpn5XW17z80DZFU
link.rule.ids 312,782,786,787,11655,11695,34254,34256,44056,74580,79428
linkProvider ProQuest
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ07T8MwEIBPtEiAQOItHgUswRrRJJZjLzCQliDSLnRgi2zH6ZZCSwb-PXdpIiqGLoyWJeuks87fPXwHcGekkVxTUbt0wuM5OqxKa-1ZE_rOCmlcrenkLRq_y3hAbXIe2r8wVFbZ2sTaUOczSzHy-4BLam4WSfX48enR1CjKrjYjNDqwyZE86IY_r-JP663vqUhJoXzq90UT0v-Y3fotGe7_V4oD2I1XkuiHsOHKI9gaNUnyY-gvQ3GMBnYiXDPEUpYiUnoIllPH0KyxeF5NGZ5iqYDz-wRuh4PJU-K1wmTNDVtkv5KEp9AtZ6U7AxYi_msTcNePkDSEM0XB_UBoVeDSSnEOvXUnXazfvoHtZDJKs_Rl_HoJO4gOahmM6EH3a165K-gs8uq61sEPIwyUOw
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEB5shSIVfFO16oJeQ5tk3cfJg2moWougB29hN9n0lmprDv57Z9IEi4eePC4LwyyzzH7z2PkAbqyyihtqaldOeDzDgFUbY7zUhr5LhbKusvT4VU7fVTSiMTmPzV8YaqtsfGLlqLN5SjnyQcAVDTeTSg_yui3iJYrvPj49YpCiSmtNp9GCbclvVUXjsA6Fmsh9V0uthPZp9hexpf9xwdW7Eu_9p0b70I3WiusHsOWKQ-g818XzIxiuUnSMiDwRdDOEq2yCUNNDwDlzDN0dixbljKGUlBo7v4_hOh693Y-9RrGkvnnL5Fer8ATaxbxwPWAhhgXGBtwNJSIQ4Wyecz8QRue4TJU4hf4mSWebt6-ggwdPJg_Tp3PYQUShVzmKPrS_FqW7gNYyKy8rc_wA0TOc_g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&rft.genre=dissertation&rft.title=Public+Support+for+Late-Stage+New+Drug+Discovery&rft.DBID=04Z%3B054%3B0BH%3B0H%7E%3BAMEAF%3BCBPLH%3BEU9%3BG20%3BM8-%3BP6D%3BPQEST%3BPQQKQ%3BPQUKI&rft.PQPubID=18750&rft.au=Nayak%2C+Rahul+K&rft.date=2019-01-01&rft.pub=ProQuest+Dissertations+%26+Theses&rft.isbn=9798691239373&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9798691239373/lc.gif&client=summon&freeimage=true
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9798691239373/mc.gif&client=summon&freeimage=true
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=9798691239373/sc.gif&client=summon&freeimage=true